Page 50 - Read Online
P. 50

Page 285                Hervas et al. J Transl Genet Genom 2021;5:278-87  https://dx.doi.org/10.20517/jtgg.2021.25

               Genotyping, data analyses, and results interpretation: Serra-Llovich A, Cárcel M, Amasi-Hartoonian N,
               Hernandez M
               Sample recrutiment and results interpretation: Rueda I, Targa I, Guijarro S, Bigorra A, Cancino M, Bote V
               Study design, data analyses, results interpretation, and paper writing: Arranz MJ


               Availability of data and materials
               Clinical and genotyping data were collected by our team and can be provided on request.

               Financial support and sponsorship
               Fondos Investigación Sanitaria, Instituto de Salud Carlos III, PI11/0260.

               Conflicts of interest
               Dr. Amaia Hervas has consulted for Exeltis and given seminars sponsored by Shire. Dr. Hervas participates
               in several clinical trials. None of these activities have influenced the present study. No other interests were
               declared by the rest of the co-authors.


               Ethical approval and consent to participate
               This study complies with the Declaration of Helsinki and has been approved by our Hospital Ethics
               Committee, as mentioned in the methods section. Informed consent was obtained from all participants or
               their legal carers prior to introduction in the study.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2021.


               REFERENCES
               1.       Brown JT, Eum S, Cook EH, Bishop JR. Pharmacogenomics of autism spectrum disorder. Pharmacogenomics 2017;18:403-14.  DOI
                   PubMed
               2.       Dodsworth T, Kim DD, Procyshyn RM, Ross CJ, Honer WG, Barr AM. A systematic review of the effects of CYP2D6 phenotypes on
                   risperidone treatment in children and adolescents. Child Adolesc Psychiatry Ment Health 2018;12:37.  DOI  PubMed  PMC
               3.       Arranz MJ, Blanco JP, Samperiz BA. Pharmacogenetics of the efficacy of antipsychotic drugs in schizophrenia. In: Rybakowski JK,
                   Serretti A, editors. Genetic influences on response to drug treatment for major psychiatric disorders. Cham: Springer International
                   Publishing; 2016. p. 1-20.  DOI
               4.       Fabbri C, Serretti A. Pharmacogenetics of the efficacy and side effects of antidepressant drugs. In: Rybakowski JK, Serretti A, editors.
                   Genetic influences on response to drug treatment for major psychiatric disorders. Cham: Springer International Publishing; 2016. p.
                   39-54.  DOI
               5.       Fabbri C, Hosak L, Mössner R, et al. Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene
                   expression markers of major depressive disorder and antidepressant response. World J Biol Psychiatry 2017;18:5-28.  DOI  PubMed
               6.       Pagerols M, Richarte V, Sánchez-Mora C, et al. Pharmacogenetics of methylphenidate response and tolerability in attention-
                   deficit/hyperactivity disorder. Pharmacogenomics J 2017;17:98-104.  DOI  PubMed
               7.       Joensen B, Meyer M, Aagaard L. Specific genes associated with adverse events of methylphenidate use in the pediatric population: a
                   systematic literature review. J Res Pharm Pract 2017;6:65-72.  DOI  PubMed  PMC
               8.       Purper-Ouakil D. [Use of psychotropic drugs in children]. Arch Pediatr 2008;15:1834-6.  DOI  PubMed
               9.       Gomez-Sanchez  CI,  Carballo  JJ,  Riveiro-Alvarez  R,  et  al.  Pharmacogenetics  of  methylphenidate  in  childhood  attention-
                   deficit/hyperactivity disorder: long-term effects. Sci Rep 2017;7:10391.  DOI  PubMed  PMC
               10.      Naumova D, Grizenko N, Sengupta SM, Joober R. DRD4 exon 3 genotype and ADHD: Randomised pharmacodynamic investigation
                   of treatment response to methylphenidate. World J Biol Psychiatry 2019;20:486-95.  DOI  PubMed
               11.      Myer NM, Boland JR, Faraone SV. Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. Mol Psychiatry
                   2018;23:1929-36.  DOI  PubMed  PMC
               12.      Fageera W, Chaumette B, Fortier MÈ, et al. Association between COMT methylation and response to treatment in children with
                   ADHD. J Psychiatr Res 2021;135:86-93.  DOI  PubMed
               13.      Bonvicini C, Faraone SV, Scassellati C. Attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis of
                   genetic, pharmacogenetic and biochemical studies. Mol Psychiatry 2016;21:872-84.  DOI  PubMed  PMC
               14.      McCracken JT, Badashova KK, Posey DJ, et al. Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic
   45   46   47   48   49   50   51   52   53   54   55